Imipramine N-oxide [6829-98-7]
Cat# T74205-10mg
Size : 10mg
Brand : TargetMol
Contact local distributor :
Phone : +1 850 650 7790
Imipramine N-oxide
Copy Product Info
Imipramine N-oxide is a tricyclic antidepressant (TCA) and imipramine analogue used to treat depression. Imipramine N-oxide can be reduced to imipramine in vitro within rat tissue homogenates or blood.
Cas No. 6829-98-7
For research use only—not for human use. No sales to individuals. Use as intended only.
Select Batch
Purity:99.80%
Appearance:Solid
Color:White
COA LCMS HNMR
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | Imipramine N-oxide is a tricyclic antidepressant (TCA) and imipramine analogue used to treat depression. Imipramine N-oxide can be reduced to imipramine in vitro within rat tissue homogenates or blood. |
| Molecular Weight | 296.41 |
| Formula | C19H24N2O |
| Cas No. | 6829-98-7 |
| Smiles | O=N(C)(C)CCCN1C=2C=CC=CC2CCC=3C=CC=CC31 |
| Storage | Store at low temperature Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (269.9 mM) | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (11.13 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||||||||||||